Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Long-Term Investments (2021 - 2023)

Historic Long-Term Investments for Cullinan Therapeutics (CGEM) over the last 3 years, with Q3 2023 value amounting to $15.5 million.

  • Cullinan Therapeutics' Long-Term Investments fell 4951.14% to $15.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $15.5 million, marking a year-over-year decrease of 4951.14%. This contributed to the annual value of $80.9 million for FY2022, which is 4239.05% down from last year.
  • Latest data reveals that Cullinan Therapeutics reported Long-Term Investments of $15.5 million as of Q3 2023, which was down 4951.14% from $20.3 million recorded in Q2 2023.
  • Cullinan Therapeutics' Long-Term Investments' 5-year high stood at $140.4 million during Q4 2021, with a 5-year trough of $15.5 million in Q3 2023.
  • Its 3-year average for Long-Term Investments is $74.2 million, with a median of $80.9 million in 2022.
  • Data for Cullinan Therapeutics' Long-Term Investments shows a peak YoY increase of 19709.45% (in 2022) and a maximum YoY decrease of 7530.76% (in 2022) over the last 5 years.
  • Over the past 3 years, Cullinan Therapeutics' Long-Term Investments (Quarter) stood at $140.4 million in 2021, then crashed by 42.39% to $80.9 million in 2022, then crashed by 80.84% to $15.5 million in 2023.
  • Its Long-Term Investments stands at $15.5 million for Q3 2023, versus $20.3 million for Q2 2023 and $112.8 million for Q1 2023.